Novel vaccine protects mice against Staphylococcus aureus infection, say researchers
The novel vaccine 4X-SA-GP harnesses the anti-fungal immune response to provide immunity against Staphylococcus aureus (S. aureus) infection.
List view / Grid view
The novel vaccine 4X-SA-GP harnesses the anti-fungal immune response to provide immunity against Staphylococcus aureus (S. aureus) infection.
Using cryogenic electron microscopy, scientists have observed the interaction between antibodies and their target molecules, providing information that could be utilised in the development of synthetic antibodies.
A potential COVID-19 vaccine, made from a modified vesicular stomatitis virus with the SARS-CoV-2 Spike protein, was shown to protect mice against the virus.
Researchers have found that the SARS-CoV-2 nucleocapsid protein may help the virus to spread from cell to cell, providing a drug target.
A protein called PPP1R1B has been revealed as a drug target for pancreatic cancer as it stopped the metastasis of tumours in mice.
Researchers have shown that using antisense oligonucleotides to reduce the levels of prion protein in lab animals with prion disease can extended their survival.
The SARS-CoV-2 Spike protein from a COVID-19 vaccine candidate has been characterised by researchers, supporting the neutralising antibody response it elicits.
A flow mode Raman-activated cell sorter called FlowRACS has been created by researchers for high-throughput discovery of enzymes and their cell factories.
A phenotypic chemical screen has been developed that could be used to discover molecular glue degraders which induce the degradation of target proteins.
According to researchers, drugs that target envelope protein E on the SARS viral membrane could also be used to target a similar protein on COVID-19.
Researchers have been able to manipulate the lifespans of C. elegans by altering the VRK-1 protein, offering a potential target hope for anti-ageing drugs.
A study has demonstrated that the LY6E protein inhibits SARS-CoV-2 infection in human cell cultures, so a drug mimicking it could be a therapy for COVID-19.
Dr Santosh Mishra and Srisruti Bontala explain how they discovered a new cutaneous-nerve pathway for allergic itch in atopic dermatitis.
Researchers have modified the COVID-19 Spike protein for use in vaccines, which produces up to 10 times more protein than that of an earlier synthetic versions.
Researchers suggest the SRPX2 protein, which inhibits complement system-dependent synapse removal could be a target for novel Alzheimer’s and schizophrenia therapies.